Related Experiment Videos
Colesevelam hydrochloride.
1Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center Presbyterian, School of Pharmacy, University of Pittsburgh, PA 15261, USA. steinmetzkl@msx.upmc.edu
Summary
Colesevelam hydrochloride effectively lowers LDL cholesterol by binding bile acids in the gut. This lipid-lowering agent offers improved efficacy and compliance compared to older bile acid sequestrants.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Primary hypercholesterolemia necessitates effective lipid-lowering agents.
- Traditional bile acid sequestrants (BASs) face challenges with efficacy and patient compliance.
Purpose of the Study:
- To review the pharmacology, pharmacodynamics, clinical efficacy, drug interactions, adverse effects, and administration of colesevelam hydrochloride.
- To evaluate colesevelam hydrochloride as a nonabsorbed lipid-lowering agent for LDL cholesterol reduction.
Main Methods:
- Review of existing literature on colesevelam hydrochloride.
- Analysis of clinical trial data for efficacy and safety.
- Pharmacological assessment of bile acid binding and lipid level changes.
Main Results:
- Colesevelam hydrochloride is a potent, nonabsorbed BAS, 4-6 times more effective than traditional agents.
- It demonstrates dose-dependent LDL cholesterol reduction, superior to placebo and comparable to statins when used in combination.
- Adverse effects are minimal, with significantly better compliance (93%) compared to traditional BASs, and few drug interactions.
Conclusions:
- Colesevelam hydrochloride is an effective alternative for managing hypercholesterolemia.
- It offers enhanced efficacy and improved patient compliance due to fewer adverse effects.
- Further studies are warranted for direct comparative analysis with traditional BASs.